Abstract :

The spread of coronavirus disease (COVID-19) led to a world-shattering pandemic which impacted humanity in a severe manner. Research suggests that coronavirus has multiorgan effects. It has brought together researchers of all fields who are trying to understand the pathophysiology of the disease and define most select treatment strategies. Pre-existing comorbidities such as hypertension, cardiovascular disease (CVD) and diabetes are linked with a higher mortality rate of COVID-19. With its widespread effects and different strains, there is escalating apprehension about the cardiovascular effects of the viral infection, like myocarditis, thrombosis and arrhythmias, and its relation with existing CVD and heart related problems. The cardiovascular manifestations of COVID-19 need to be understood well for cardiologists and other health workers to be able to diagnose and treat them in the upcoming time.

---

Keywords :

Arrhythmia; Cardiovascular; COVID-19; Myocarditis; Thrombosis

---

References :

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020 Feb 15;395(10223):497-506.
2. E Conhecimento RD. Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE).
3. Judson GL, Kelemen BW, Njoroge JN, Mahadevan VS. Cardiovascular implications and therapeutic considerations in COVID-19 infection. Cardiology and Therapy. 2020 Jun 13:1-3.
4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020 Mar 17;323(11):1061-9.
5. Zhang J, Lu S, Wang X, Jia X, Li J, Lei H, Liu Z, Liao F, Ji M, Lv X, Kang J. Do underlying cardiovascular diseases have any impact on hospitalised patients with COVID-19?. Heart. 2020 Aug 1;106(15):1148-53.
6. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, Tobin KA, Cerfolio RJ, Francois F, Horwitz LI. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. Bmj. 2020 May 22;369.
7. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA cardiology. 2020 Jul 1;5(7):811-8.
8. Blauwet LA, Cooper LT. Myocarditis. Progress in cardiovascular diseases. 2010 Jan 1;52(4):274-88.
9. Zeng JH, Liu YX, Yuan J, Wang FX, Wu WB, Li JX, Wang LF, Gao H, Wang Y, Dong CF, Li YJ. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection. 2020 Oct;48(5):773-7.
10. Mele D, Flamigni F, Rapezzi C, Ferrari R. Myocarditis in COVID-19 patients: current problems. Internal and Emergency Medicine. 2021 Jan 23:1-7.
11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020 Mar 28;395(10229):1054-62.
12. Chen T, Wu DI, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. bmj. 2020 Mar 26;368.
13. Cannatà A, Bromage DI, Rind IA, Gregorio C, Bannister C, Albarjas M, Piper S, Shah AM, McDonagh TA. Temporal trends in decompensated heart failure and outcomes during COVID‐19: a multisite report from heart failure referral centres in London. European journal of heart failure. 2020 Dec;22(12):2219-24.
14. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, Ibrahim H, Friedman GH, Thompson C, Alviar CL, Chadow HL. ST-segment elevation in patients with Covid-19—a case series. New England Journal of Medicine. 2020 Jun 18;382(25):2478-80.
15. Ashraf S, Ilyas S, Alraies MC. Acute coronary syndrome in the time of the COVID-19 pandemic. European Heart Journal. 2020 Jun 7;41(22):2089-91.
16. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MC, Bouman CC, Beenen LF, Kootte RS, Heijmans J, Smits LP. Incidence of venous thromboembolism in hospitalized patients with COVID‐ Journal of Thrombosis and Haemostasis. 2020 Aug;18(8):1995-2002.
17. Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, Kucher N, Studt JD, Sacco C, Alexia B, Sandri MT. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis research. 2020 Jul 1;191:9-14.
18. Price LC, McCabe C, Garfield B, Wort SJ. Thrombosis and COVID-19 pneumonia: the clot thickens!.
19. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis. 2020 May;18(5):1094-9.
20. Dherange P, Lang J, Qian P, Oberfeld B, Sauer WH, Koplan B, Tedrow U. Arrhythmias and COVID-19: a review. JACC: Clinical Electrophysiology. 2020 Aug 10.
21. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA cardiology. 2020 Jul 1;5(7):811-8.
22. Kochi AN, Tagliari AP, Forleo GB, Fassini GM, Tondo C. Cardiac and arrhythmic complications in patients with COVID‐ Journal of cardiovascular electrophysiology. 2020 May;31(5):1003-8.
23. Colon CM, Barrios JG, Chiles JW, McElwee SK, Russell DW, Maddox WR, Kay GN. Atrial arrhythmias in COVID-19 patients. Clinical Electrophysiology. 2020 Sep 1;6(9):1189-90.
24. Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action. British journal of haematology. 2020 Jun;189(5):846-7.
25. Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Elife. 2020 Apr 6;9:e57278.
26. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The lancet. 2020 Mar 28;395(10229):1033-4.
27. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., Shi, Z., Hu, Z., Zhong, W., & Xiao, G. (2020, February 4). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Nature News.
28. Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020 Apr 1;55(4):105945.
29. Simoens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respiratory medicine. 2013 May 1;107(5):637-48.
30. White NJ. Cardiotoxicity of antimalarial drugs. The Lancet infectious diseases. 2007 Aug 1;7(8):549-58.
31. Ukimura, A. (2013, January 1). A national survey on myocarditis associated with influenza H1N1pdm2009 in the pandemic and postpandemic season in Japan. Journal of Infection and Chemotherapy.